Drug Landscape ›
Influenzae vaccine ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 41
Most-reported reactions
Arthralgia — 5 reports (12.2%) Malaise — 5 reports (12.2%) Therapeutic Product Effect Decreased — 5 reports (12.2%) Contraindicated Product Administered — 4 reports (9.76%) Drug Ineffective — 4 reports (9.76%) Epicondylitis — 4 reports (9.76%) Musculoskeletal Pain — 4 reports (9.76%) Rheumatoid Arthritis — 4 reports (9.76%) Condition Aggravated — 3 reports (7.32%) Pain — 3 reports (7.32%)
Source database →
Influenzae vaccine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Influenzae vaccine approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Influenzae vaccine in United States?
PT Bio Farma is the originator. The local marketing authorisation holder may differ — check the official source linked above.